BOLERO-2 erratum corrected abstract sentence

BOLERO-2 erratum 的最终可引用摘要句

来源：PMC4713958（Erratum to: Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis）

''被更正的唯一摘要句末尾''：
原句写作 “... in the overall population and in all prospectively defined subgroups, including patients with visceral metastases, patients with recurrence during or within 12 months of completion of adjuvant therapy, and irrespective of age.”

''修订后应引用的句子''：
“Final study results with median 18-month follow-up show that median PFS remained significantly longer with everolimus plus exemestane versus placebo plus exemestane [investigator review: 7.8 versus 3.2 months, respectively; hazard ratio = 0.45 (95% confidence interval 0.38–0.54); log-rank P < 0.0001; central review: 11.0 versus 4.1 months, respectively; hazard ratio = 0.38 (95% confidence interval 0.31–0.48); log-rank P < 0.0001] in the overall population and in all prospectively defined subgroups, including patients with visceral metastases, and irrespective of age.”

''关键差异''：
- 删除了 “patients with recurrence during or within 12 months of completion of adjuvant therapy” 这一亚组表述。
- 其余 PFS 数值、HR、CI、P 值未改。

可复现核查：直接读取 PMC4713958 页面正文，搜索 “The correct sentence should read” 即可定位修订句。